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Abstract
Background: S1PL is an aldehyde-lyase that irreversibly cleaves sphingosine 1-phosphate (S1P) in the terminal step of
sphingolipid catabolism. Because S1P modulates a wide range of physiological processes, its concentration must be tightly
regulated within both intracellular and extracellular environments.
Methodology: In order to better understand the function of S1PL in this regulatory pathway, we assessed the in vivo effects
of different levels of S1PL activity using knockout (KO) and humanized mouse models.
Principal Findings: Our analysis showed that all S1PL-deficient genetic models in this study displayed lymphopenia, with
sequestration of mature T cells in the thymus and lymph nodes. In addition to the lymphoid phenotypes, S1PL KO mice
(S1PL
2/2) also developed myeloid cell hyperplasia and significant lesions in the lung, heart, urinary tract, and bone, and had
a markedly reduced life span. The humanized knock-in mice harboring one allele (S1PL
H/2) or two alleles (S1PL
H/H) of human
S1PL expressed less than 10 and 20% of normal S1PL activity, respectively. This partial restoration of S1PL activity was
sufficient to fully protect both humanized mouse lines from the lethal non-lymphoid lesions that developed in S1PL
2/2
mice, but failed to restore normal T-cell development and trafficking. Detailed analysis of T-cell compartments indicated
that complete absence of S1PL affected both maturation/development and egress of mature T cells from the thymus,
whereas low level S1PL activity affected T-cell egress more than differentiation.
Significance: These findings demonstrate that lymphocyte trafficking is particularly sensitive to variations in S1PL activity
and suggest that there is a window in which partial inhibition of S1PL could produce therapeutic levels of
immunosuppression without causing clinically significant S1P-related lesions in non-lymphoid target organs.
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Introduction
Sphingosine 1-phosphate (S1P), a breakdown product of
sphingolipid metabolism [1–5], is present in all mammalian cells
and serves as second messengerin signal transductionpathways that
regulate cell differentiation, proliferation, and apoptosis -[1–13].
S1P is also released into the extracellular milieu by a variety of cell
types, making it one of the most abundant biologically active
lysophospholipids in circulation [2,4,14]. Autocrine and paracrine
interactions between S1P and a family of G protein-coupled
receptors (S1P1–S1P5) have been implicated in a wide range of
physiological activities, including cardiovascular development and
disease, neuronal cell survival, and immunity [1,2,4,9,10,12,14–16].
Systemic and local concentrations of S1P are regulated directly
by three classes of enzymes within the sphingolipid pathway.
Reversible synthesis of S1P is mediated by sphingosine kinases
[2,3,10], which phosphorylate sphingosine to produce S1P, and by
S1P phosphatases [4,14], which remove the phosphate. Irrevers-
ible degradation of S1P is carried out by a single enzyme,
Sphingosine 1-phosphate lyase (S1PL), which cleaves S1P into
ethanolamine phosphate and a long chain aldehyde [4,12–
14,17,18]. S1PL is present in most mammalian cells except for
platelets and erythrocytes [4,14,19], but its relative abundance
varies by tissue and cell type.
The diverse effects of S1P make it difficult to dissect its role in
different aspects of mammalian physiology and to predict the in
vivo consequences of deficiency in S1P degrading enzymes,
including S1PL. Disrupted lipid metabolism due to mutations in
the catabolic enzymes of the sphingolipid pathway can result in
sphingolipid storage diseases, which are characterized by the
cellular storage and accumulation of the sphingolipid substrates
[20]. The specific pathologic phenotype associated with each
sphingolipid storage disease depends on both the expression
pattern of the affected catabolic enzyme and the metabolic burden
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associated with S1PL deficiency, loss of S1PL in mice leads to
stunted growth and early mortality, with defects reported in the
kidney, bone, vasculature and myeloid cell lineages [21].
In the immune system, changes in local S1P concentration and
gradient can alter inflammatory cell responses [22,23], affect the
barrier function of endothelial cells [24–26], and modify
lymphocyte migration patterns [15,16,27–29]. Hematopoietic
cell-specific knockdown of S1PL in the bone-marrow using RNA
interference increased S1P levels in lymphoid organs and lead to
lymphopenia after transplantation of the bone marrow into
immunodeficient mice [28]. The described effect of S1PL
knockdown is similar to that observed after treatment with the
S1P-analog FTY720[29]. S1P and FTY720 elicit their effects on
the immune system through interaction with the S1P1 receptor,
which inhibits lymphocyte egress from primary and secondary
lymphoid organs and in turn reduces the number of recirculating
lymphocytes in peripheral blood [27,30–35]. One physiological
outcome of this systemic redistribution of lymphocytes is potent
immunosuppression, which offers new opportunities for develop-
ing immunoregulatory agents to treat autoimmune and inflam-
matory diseases [36–40]. The S1P1 receptor is currently a target of
pharmaceutical development, and enzymes of the S1P metabolic
pathway may provide additional intervention points for improved
therapeutic applications.
In this study, we determined the levels of S1PL enzyme activity
in gene knockout and humanized mouse models of S1PL
deficiency and compared the in vivo immunological and patholog-
ical effects associated with different levels of S1PL enzyme activity.
Our findings show that effects on the immune system, typically
characterized by lymphopenia and alterations in lymphoid tissues,
were present in all mice with reduced or absent S1PL activity.
These results indicate that the immune system is particularly
sensitive to alterations in S1PL activity. In contrast, the storage
disease phenotype in knockout mice that was characterized by
alveolar proteinosis, cardiomyopathy, osteopetrosis and urothelial
vacuolization in KO mice was prevented by restoration of even
low level S1PL activity in humanized mice. In summary, our
findings suggest that partial inhibition of S1PL activity can
produce potentially therapeutic immunosuppression without
causing S1P-related storage disease lesions in non-lymphoid target
organs.
Results
S1PL is required for normal development in mice
S1PL-null mice were derived from an OmniBank [41]
embryonic stem cell clone (OST58278) carrying a gene trap
mutation within the second intron of the S1PL gene (Fig. 1A and
B) Heterozygous mice (S1PL
+/2) were viable and fertile and were
intercrossed to obtain homozygous progeny. Over 900 offspring
were produced in an essentially normal (1:2:1) Mendelian
distribution (26.3% wild type (Wt; S1PL
+/+), 52.1% S1PL
+/2,
21.6% S1PL
2/2), suggesting that S1PL is not essential for
embryonic development and neonatal viability. S1PL activity
was undetectable in S1PL
2/2 mice, and was accompanied by
Figure 1. Generation of S1PL mutant mice. (A) Gene trap mutation of the S1PL gene. The insertion occurred within intron 2 of the S1PL gene
(NM_009163). LTR, viral long terminal repeat; SA, splice acceptor sequence; IRES, internal ribosome entry site; bGeo, fusion of beta-galactosidase and
neomycin phosphotransferase genes; pA, polyadenylation sequence; PGK, phosphoglycerate kinase-1 promoter; BTK-SD, Bruton’s tyrosine kinase
splice donor sequence. (B) Genotyping strategy. Primers F (59-TGTAGCAGGCTTTCTTAACTCTGG-39) and R (59-TTGGGAAGGTCCTGGTCATTACT-39) flank
the genomic insertion site and amplify a product of 321 nucleotides representing the Wt allele. The LTRrev primer (59-ATAAACCCTCTTGCAGTTG-
CATC-39), complementary to the gene trapping vector, amplifies a 193 nucleotide mutant allele in conjunction with primer F. (C) S1PL activity and
S1P concentration were measured in spleen samples of the indicated mice. Enzyme activity was normalized to the mean of the Wt values; 100%
corresponds to 172,898615,344 cpm/mg/hr. Data were pooled from 2 experiments using 4–8 mice of each genotype, and data are presented as
mean6SEM. * Activity was below the sensitivity of detection.
doi:10.1371/journal.pone.0004112.g001
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fold increase in KO mice compared to Wt). The S1PL
2/2 mice
were smaller than their Wt littermates and failed to thrive during
the first weeks of life (bodyweight 15.560.7 g, S1PL
+/+,n = 2 3
versus 10.360.4 g, S1PL
2/2, n=20, at 4 weeks of age,
p=3 610
27). All S1PL
2/2 mice in our study died by 15 weeks
of age, having a median life span of 29 days (min. 22 days, max.
105 days, n=55). The reduced viability and blood phenotype
(described later) of this S1PL
2/2 gene-trap line was recapitulated
in another S1PL knockout mouse line generated by homologous
recombination in which exons 7–8 were replaced by a cre-lox
selection cassette (data not shown).
S1PL
2/2 mice are lymphopenic due to altered
lymphocyte development and tissue egress
Complete blood cell count (CBC) and flow cytometry (FACS)
analysis of peripheral blood of 4 week old S1PL
2/2 mice revealed
an almost complete absence of peripheral T cells as well as severely
reduced numbers of B cells compared to Wt values (Fig. 2A and
B). Despite the severe lymphopenia, the total white blood cell
counts of S1PL
2/2 mice were within the normal range due to a
significant increase in monocyte and neutrophil numbers.
Likewise, red blood cell counts in the S1PL2/2 mice were not
significantly different than those of Wt littermates (Wt 8.2+/
20.38, Hom 7.4+/20.37 p=0.12). Analysis of lymphoid tissues
from S1PL
2/2 mice demonstrated decreased size and cellularity
when cell counts were normalized to body weight (Fig. 2A). The
thymus of S1PL
2/2 animals showed the most pronounced
lymphocyte depletion, harboring only approximately 10% the
number of lymphocytes seen in S1PL
+/+ mice. The total
lymphocyte numbers in S1PL
2/2 lymph nodes and spleens were
57% and 43% of those observed in Wt littermates, respectively.
The altered lymphocyte counts in S1PL
2/2 mice were similar
to those reported following modulation of the S1P-S1P1 receptor
axis [28,31,34,38,39,42]. Therefore, we assessed the phenotypes of
lymphocyte subpopulations residing in the immune tissues by
using markers of cell differentiation and lymphocyte egress, such as
CD69 and a series of cell adhesion molecules (Fig. 2 and 3). The
thymus of S1PL
2/2 mice showed a severe depletion of CD4 and
CD8 double positive (DP) thymocytes compared to controls, but
we did not observe an increase in the CD4 and CD8 double
negative (DN) cell population as would be expected from a block at
the DN to DP transition stage (Fig. 2B). Instead, the proportion of
mature CD4 and CD8 single positive (SP) cells was 5-fold higher
in the age-matched S1PL
2/2 mice compared to Wt littermates.
The S1PL
2/2 mature thymocytes had normal surface density of
the TCR and the coupled CD3 molecule (data not shown), but
completely lacked the expression of CD69, a marker of early
medullary thymocytes, which constitute the majority of SP
thymocytes in normal controls (Fig. 3A). The S1PL
2/2 SP
thymocytes also showed relatively high expression of CD62L and
b7 integrin, but reduced levels of CD24 and CD44 molecules
(Fig. 3B). These phenotypic changes in the S1PL
2/2 mature
thymocyte population are consistent with a block in the migration
of lymphocytes into the periphery and a concomitant accumula-
tion of mature thymocytes in the thymus of the S1PL-deficient
animals [28,38,39,42,43].
Histopathological analysis of thymus from S1PL
2/2 mice
revealed severe cortical lymphoid depletion with concurrent
medullary hypercellularity. The thymic cortex of normal age-
matched S1PL
+/+ mice was densely packed with thymic
lymphocytes and thus appeared to be broader and more cellular
than the thymic medulla (Fig. 4A). This arrangement was
essentially reversed in the thymus of S1PL
2/2 mice, where the
hypoplastic thymic cortex appeared as a thin pale hypocellular
zone due to the severe, diffuse depletion of thymic lymphocytes
(Fig. 4B, upper panel); the few remaining cells in the thymic cortex
consisted of vacuolated stromal/epithelial cells mixed with smaller
numbers of granulocytes, macrophages, lymphocytes, and apo-
ptotic cells. In contrast, the markedly expanded and hypercellular
thymic medulla of S1PL
2/2 mice contained numerous mature
lymphocytes as well as vacuolated stromal/epithelial cells,
macrophages, and histiocytes (Fig. 4B, lower panel).
FACS analysis of cell suspensions from the secondary lymphoid
organs revealed that loss of S1PL had more consistent effects on T-
cell content than B-cell content of these tissues. S1PL
2/2 mice
registered only 25% of normal T-lymphocyte counts in the lymph
Figure 2. KO of S1PL disrupts both development and recirculation of lymphocytes. (A and B) Hematopoietic cell profile of the indicated
tissues from S1PL
+/+ (black bars) and S1PL
2/2 (white bars) mice determined by CBC and FACS analysis. Data are presented as mean6SEM values
obtained from 11–18 mice of each genotype pooled from two independent experiments giving similar results. Numbers above bars indicate P values,
*P,2610
24,* * P,0.05, S1PL
2/2 vs. S1PL
+/+. Lymph, lymphocytes; Mono, monocytes; Neutro, neutrophil granulocytes.
doi:10.1371/journal.pone.0004112.g002
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of the Wt level in the spleen, it was not significantly different in the
lymph nodes (Fig. 2B). Histological analysis of S1PL
2/2 lymph
nodes and intestinal mucosa showed that cell types and
distributions differed from Wt mouse tissues (Fig. 5A). The
S1PL
2/2 lymph nodes contained smaller B cell follicles and
reduced numbers of lymphocytes in paracortical zones (Fig. 5B,
upper panel). In mesenteric lymph nodes, lymphoid follicles
appeared as small semicircular caps overlying expanded but
relatively hypocellular paracortical zones (Fig. 5B, upper panel).
The paracortex contained reduced numbers of lymphocytes, but
markedly increased numbers of granulocytes and macrophages
(some vacuolated and containing karyorrhectic debris), mixed with
stromal cells and plasma cells (Fig. 5B, middle panel). The
paracortex also showed a mild increase in collagenous stroma. The
reduced numbers of lymphocytes and increased numbers of
granulocytes in the paracortical areas of the mesenteric lymph
nodes were mirrored by depletion of lymphocytes and increased
numbers of granulocytes in the lamina propria of the small
intestine (Fig. 5B, lower panel). In the spleen, the normal
arrangement of periarteriolar lymphoid sheaths (PALS) and
lymphoid follicles in the white pulp of Wt (Fig. 6A) was disrupted
in S1PL
2/2 mice (Fig. 6B). The most notable finding was severe
depletion of T cells in the PALS in the S1PL
2/2 spleen (Fig. 6B,
lower panel). In contrast, B cell areas were relatively unaffected,
with remaining lymphoid follicles and some germinal centers
appearing more prominent due to the depletion of PALS. Other
findings in the spleen included occasional clusters of plasma cells in
the PALS and increased erythroid hematopoiesis in red pulp of
S1PL
2/2 mice.
In the bone marrow, FACS analysis showed a lower ratio of
mononuclear cells to granulocytes in S1PL
2/2 compared to
S1PL
+/+ mice as defined by the distinguishing scatter parameters
(Fig. 7) and expression of the cell surface marker GR-1 (data not
shown). In addition, the fraction of pre-B cells was significantly
reduced in the S1PL
2/2 bone marrow, while the pro-B cell and
mature B-cell subsets were present at their usual frequency (Fig. 7).
Histopathological examination also showed increased granulocy-
topoiesis in the bone marrow of S1PL
2/2 mice (data nor shown).
In summary, comparative assessment of the peripheral blood
and primary and secondary lymphoid tissues indicated that the
severe lymphopenia in S1PL
2/2 mice was due to alterations in the
Figure 3. Absence of S1PL leads to accumulation of mature medullary thymocytes. (A) Representative FACS histograms of expression of
the CD69 and CD62L markers on S1PL
+/+ (shaded histograms) and S1PL
2/2 (open histograms) CD4 and CD8 SP thymocytes. The fraction of
electronically gated CD4 and CD8 SP thymocytes that exhibit the indicated phenotypes (demarcated by the solid vertical lines) are depicted in
graphical form. Datapoints represent values from individual S1PL
+/+ (grey circles) and S1PL
2/2 (white circles) mice. Vertical dashed lines on the CD62L
histograms indicate the cut-off values for positive staining obtained with isotype-matched control antibodies, which overlapped with the solid lines
on the CD69 histograms. (B) Representative FACS histograms of CD24, CD44, and b7 integrin density on S1PL
+/+ (shaded histograms) and S1PL
2/2
(open histograms) SP thymocytes, gated for single expression of either the CD4 or CD8 markers. Vertical dashed lines represent cut-off values as in
(A). Samples from two additional mice of each genotype gave similar results.
doi:10.1371/journal.pone.0004112.g003
S1P Lyase Deficiency in Mice
PLoS ONE | www.plosone.org 4 January 2009 | Volume 4 | Issue 1 | e4112development and recirculation of lymphocytes, with the greatest
impact on T-cell differentiation and egress.
Effects of complete S1PL deficiency on non-lymphoid
tissues
Histopathology of lungs from S1PL
2/2 mice revealed that
virtually all pulmonary alveoli contained variable amounts of
variably sized irregularly shaped polygonal flakes and clumps of
smooth homogenous (hyaline) material (Fig. 8B). This proteina-
ceous material was generally free in the lumen but in many
locations formed a thin layer lining the surface of alveolar septa.
Associated with this alveolar exudate were markedly increased
numbers of alveolar macrophages that were often distended by an
abundant foamy and microvacuolated cytoplasm. Diffusely,
alveolar septa were also mildly thickened due to cellular
hypertrophy and collagen deposition.
Histological analysis of bone revealed an increase in the volume
and extent of trabecular bone in the sternebra and long bones of
S1PL
2/2 mutants. In comparison the bones of Wt mice (Fig. 9,
upper panels) bony trabeculae extended throughout the marrow
space in sternebrae and farther than normal into the diaphysis in long
bones (Fig. 9, lower panels). In contrast to normal osteoclasts, which
are usually tightly adherent and flattened against bone surfaces (Fig. 9
upper panels), the more numerous osteoclasts of S1PL
2/2 mice were
distended by an abundant pale and granular eosinophilic cytoplasm
that displaced cell nuclei to the periphery (Fig. 9, lower panels).
Generally, these large rounded S1PL
2/2 osteoblasts had minimal
direct contact with bone surfaces. They were present in increased
numbers around mature trabecular bone in all areas, but they were
particularly large and numerous in epiphyseal and diaphyseal regions
distant from the physeal growth plate.
Histopathologic lesions in the hearts of S1PL
2/2 mice were
characterized by patchy to diffuse expansion of the interstitium by
numerous variably-sized vacuoles and vacuolated mesenchymal
cells that separated the cardiomyocytes (Fig. 10B). Scattered
cardiomyocytes contained focal cytoplasmic lesions that ranged
from indistinct foamy inclusions to sharply demarcated clear
vacuoles and some cardiomyocytes had enlarged vesicular nuclei.
S1PL
2/2 mice also developed lesions affecting the urothelium
lining the renal pelvis, ureters, and urinary bladder. These
urothelial lesions were characterized by widespread ballooning
vacuolization, degeneration, and apoptosis of urothelial cells
(Fig. 10D). The most severe lesions were present in the superficial
umbrella cell layer of urinary bladder urothelium, where small
numbers of degenerating cells were interspersed among urothelial
cells distended by large vacuoles that were either empty or
partially filled with pale eosinophilic granular material.
Humanized knock-in mice are lymphopenic but do not
develop non-lymphoid pathologies
In order to obtain a mouse model for testing in vivo effects of
S1PL-selective compounds and to rescue the defects observed in
Figure 4. Histopathology of Thymus. (A) S1PL
+/+ thymus: A broad thymic cortex is densely packed with thymic lymphocytes (lower panel) (B)
S1PL
2/2 thymus: The hypoplastic cortex is very thin and hypocellular due to severe cortical lymphoid depletion and apoptosis. At higher
magnification (lower panel) the remaining cells in the thymic cortex include vacuolated stromal/epithelial cells and smaller numbers of granulocytes,
macrophages, lymphocytes, and apoptotic cells. In contrast, the markedly expanded and hypercellular thymic medulla of S1PL
2/2 mice contains
numerous mature lymphocytes as well as vacuolated stromal/epithelial cells, macrophages, and histiocytes (lower panel). (C) S1PL
H/H thymus: The
cortex contains minimally decreased numbers of lymphocytes while there is a minimal expansion of the medulla by increased numbers of
lymphocytes (D) S1PL
H/2 thymus: Thinning of the thymic cortex is accompanied by mild expansion of the medulla due primarily to increased
numbers of lymphocytes (lower panel). H&E stain.
doi:10.1371/journal.pone.0004112.g004
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2/2 mice we generated mice that express a human
transgene. For this purpose, human S1PL cDNA was inserted at
the mouse S1PL locus by homologous recombination, replacing
the first exon of the mouse gene (Fig. 11). The resulting knock-in
S1PL
H/H mice exhibited S1PL activity at approximately 17% of
normal Wt levels, which correlated with increased levels of S1P in
the spleen (Fig. 11D) and serum (4-fold increase in humanized
mice compared to Wt). The limited S1PL activity in the
humanized S1PL
H/H mice alleviated the pathological findings
observed in the lungs, heart, bone, and urinary tracts of S1PL
2/2
mice, but did not rescue completely the immunological pheno-
types. Transgenic S1PL
H/H mice were viable and fertile, but
registered significantly reduced peripheral lymphocyte numbers
compared to Wt littermates (Fig. 12A). RBC numbers in the
humanized mice were indistinguishable from Wt (Wt 10.0+/
20.16, S1PLH/H 10.0+/20.19). T-cell counts in S1PL
H/H mice
Figure 6. Histopathology of Spleen. (A) S1PL
+/+ spleen: Densely packed lymphocytes comprise the thick periarteriolar sheaths (PALS) in Wt
mice. (B) S1PL
2/2 spleen: There is severe depletion of T cells in the PALS. The lymphocytes in the PALS have been replaced by small numbers of
macrophages, granulocytes, and plasma cells. B cell areas are still evident, with remaining lymphoid follicles and some germinal centers appearing
more prominent due to lymphoid depletion of PALS. (C) S1PL
H/H spleen: The splenic white pulp contains essentially normal numbers and
distributions of lymphocytes in the PALS and follicles. (D) S1PL
H/2 spleen: Again, the splenic white pulp contains essentially normal numbers and
distributions of lymphocytes in the PALS and follicles. H&E stain.
doi:10.1371/journal.pone.0004112.g006
Figure 5. Histopathology of mesenteric lymph nodes and intestinal lamina propria. (A) S1PL
+/+ lymph node: Paracortical zones are
filled primarily with lymphocytes (B) S1PL
2/2 lymph node: Small B cell lymphoid follicles appear as small semicircular caps overlying an expanded
but relatively hypocellular paracortical zones. At higher magnification (lower panel), the paracortex contains markedly increased numbers of
granulocytes and macrophages (some vacuolated and containing karyorrhectic debris), mixed with stromal cells and plasma cells. (C) S1PL
H/H
lymph node: There is marked expansion of paracortical zones. At higher expansion, this expansion is due primarily to sequestered lymphocytes. (D)
S1PL
H/2 lymph node: Similarly, the marked expansion of paracortical zones is due primarily to sequestered lymphocytes (lower panel). (E) S1PL
+/+
lamina propria: Lymphocytes and plasma cells predominate in the lamina propria of Wt mice. (F) S1PL
2/2 lamina propria: There is a marked
depletion of lymphocytes and plasma cells and increased numbers of granulocytes (arrows) in the intestinal lamina propria. (G) S1PL
H/H lamina
propria: Essentially normal cell populations are present. (H) S1PL
H/2 lamina propria: Essentially normal cell populations are present. H&E stain.
doi:10.1371/journal.pone.0004112.g005
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the indicated mice, showing the scatter distribution of CD45 positive leukocytes and the a-B220/CD43 antibody staining patterns of the mononuclear
cell fractions. Frequencies of events representing granulocytes, mononuclear cells and the B cell maturation stages are listed close to the respective
gates. Dashed rectangles indicate the cut-off values for positive staining obtained with isotype-matched control antibodies. Samples from two
additional mice of each genotype gave similar results.
doi:10.1371/journal.pone.0004112.g007
Figure 8. Histopathology of Lung. (A) S1PL
+/+ lung: Alveolar spaces are generally clear and septa are thin in Wt mice (B) S1PL
2/2 lung: Alveoli
contain variably sized irregularly shaped polygonal flakes and clumps of smooth homogenous (hyaline) material accompanied by increased numbers
of alveolar macrophages. Alveolar septa are mildly thickened due to cellular hypertrophy and collagen deposition. H&E stain.
doi:10.1371/journal.pone.0004112.g008
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blood and thymus, although not in the secondary lymphoid organs
(Fig. 12B). Similarly, reduced B-cell numbers (by about 40%) were
observed only in the peripheral blood, while monocyte and
granulocyte counts were normal. FACS analysis of the thymus of
S1PL
H/H mice showed the characteristic increase in the
Figure 9. Histopathology of Bone. S1PL
+/+ Bone (A, B, and C): In Wt mice, the majority of the marrow cavity is filled with hematopoietic
elements. Widely spaced trabeculae in long bones (A) and sternum (B) extend a relatively short distance from the physeal growth plate. At higher
magnification (C), normal osteoclasts appear as multinucleated cells that are usually tightly adherent and flattened against bone surfaces. S1PL
2/2
Bone (D, E, and F): In marked contrast, there is a diffuse increase in the volume and extent of trabecular bone in the long bones (D) and sternum (E)
S1PL
2/2 mice. The bony trabeculae extend throughout the marrow farther than normal into the diaphysis of long bones (D) and sternum (E). At
higher magnification (F), the more numerous osteoclasts of S1PL
2/2 mice are distended by abundant pale and granular eosinophilic cytoplasm that
displaces cell nuclei to the periphery. These large rounded S1PL
2/2 osteoblasts (arrows) have reduced direct contact with bone surfaces. H&E stain.
doi:10.1371/journal.pone.0004112.g009
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recent thymic emigrants (Fig. 12B) also being observed in S1PL
2/2
mice.
A histological analysis of S1PL
H/H animals at 16 weeks of age
revealed relatively mild lesions that were restricted to lymphoid
tissues and consistent with retention of mature lymphocytes in the
thymus and secondary lymphoid organs. None of the lesions seen
in S1PL
2/2 mice were noted in the lung, heart, bone, or
urothelium of young adult S1PL
H/H mice. In the thymus, the
cortex contained minimally decreased numbers of lymphocytes
(Fig. 4C upper panel) accompanied by a minimal expansion of the
medulla by increased numbers of lymphocytes (Fig. 4C lower
panel). The mesenteric and peripheral lymph nodes of S1PL
H/H
mice were characterized by marked expansion of paracortical
areas by sequestered lymphocytes (Fig. 5C). In contrast to the
severe depletion of lymphocytes in the PALS of S1PL
2/2 mice
(Fig 6B), the splenic white pulp of S1PL
H/H mice (Fig. 6C)
contained essentially normal numbers and distributions of
lymphocytes in the PALS and follicles. In aged (58 weeks)
S1PL
H/H mice, notable histopathological changes were also
limited to lymphoid tissues, although there was minimal
vacuolization of a few superficial urothelial cells in the urinary
Figure 10. Histopathology in other tissues. (A) S1PL
+/+ heart: There is minimal interstitial tissue in Wt myocardium. (B) S1PL
2/2 heart: There
is a patchy to diffuse expansion of the interstitium by numerous variably-sized vacuoles and vacuolated mesenchymal cells that separate the
cardiomyocytes. Scattered cardiomyocytes contain indistinct foamy inclusions and sharply demarcated clear vacuoles. (C) S1PL
+/+ urinary bladder:
Normal urothelium lines the urinary bladder in Wt mice (D) S1PL
2/2 urinary bladder: There is widespread ballooning vacuolization, degeneration,
and apoptosis of urothelial cell. Lesions are more severe in the superficial umbrella cell layer, where degenerating cells are interspersed among
vacuolated urothelial cells. (E) Bone, aged S1PL
H/2 mouse: Small numbers of distended osteoclasts are present multifocally at the growth plate
only. No increase in trabecular bone was evident. (F) Urinary bladder, aged S1PL
H/2 mouse: Rare vacuolated urothelial cells were present in the
superficial mucosa. H&E stain.
doi:10.1371/journal.pone.0004112.g010
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shown).
To assess the phenotypic effects of even greater decreases in
S1PL activity, we crossed S1PL
H/H with S1PL
2/2 mice to obtain
S1PL
H/2 offspring which carry a single functional copy of S1PL.
S1PL activity in these S1PL
H/2 mice was expected to be lower
than the enzyme activity in S1PL
H/H mice. In fact, S1PL activity
was below the level of detection levels of our enzymatic assay (data
not shown). These lower levels of S1PL activity in S1PL
H/2 mice
correlated with an additional significant reduction in circulating T
lymphocytes compared to S1PL
H/H animals (Fig. 13). Histopath-
ological changes in lymphoid tissues in S1PL
H/2 mice were similar
in type and severity to those seen in the S1PL
H/H line (Fig. 4D,
Fig. 5D, and Fig. 6D). Importantly, the additional reduction of
S1PL activity in the S1PL
H/2 mice still did not elicit clinically
significant lesions in any non-lymphoid tissues of young adult
mice. Similarly, aged (58 weeks) S1PL
H/2 mice also lacked lesions
in lungs or hearts, although small numbers of enlarged osteoclasts
at the physis in bones (Fig. 10E), and multifocal minimal
vacuolization and degeneration of urinary bladder urothelium
Figure 11. Generation of humanized S1PL allele. (A) Schematic representation of the S1PL allele. Entire genomic locus spanning 15 exons
indicated at the top. To create the humanized line, the coding portion of mouse exon 2 (first coding exon) was deleted and replaced with a full length
human S1PL cDNA along with a LoxP-flanked Neo marker and a minigene to allow splicing. Hs, Homo sapiens; MT II, metallothionein 2 gene; Neo,
neomycin resistance gene. (B) Genotyping strategy. Three correctly targeted clones (1D12, 1F2, 1G10) were identified by Southern blot analysis using
59 external and 39 internal probes. Lex-1, non-targeted, control ES cell DNA. (C) Expression analysis. Expression of the human S1PL gene was detected
by RT-PCR. (D) S1PL activity and S1P concentration were measured in spleen samples of the indicated mice. Data are presented as in Fig. 1C.
doi:10.1371/journal.pone.0004112.g011
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tion of trabecular bone in the metaphysis and diaphysis of long
bones were within normal limits in aged S1PL
H/2 mice.
Discussion
Comparative analysis of KO and humanized mice demonstrat-
ed differential effects of complete and partial inhibition of S1PL
activity on general physiology versus immune function. Inactiva-
tion of S1PL resulted in increased levels of S1P in tissues and
serum, and the ensuing physiological consequences correlated
proportionally with the extent of S1PL deficiency. We found that
clinically significant lesions in non-lymphoid tissues developed only
in the complete absence of S1PL activity in the S1PL
2/2 mice. In
contrast, the immune system was exquisitely sensitive to alterations
in S1PL activity even in partial absence of S1PL. Concurrent
depletion of T cells from the peripheral blood and sequestration of
mature T cells within the thymic medulla and lymph nodes were
observed in all three genetic models (S1PL
2/2, S1PL
H/H, and
S1PL
H/2 mice). The T-cell content of secondary lymphoid organs
was always less affected than would be expected from the severity
of lymphopenia in the peripheral blood, even after complete loss of
S1PL activity. Such altered redistribution of T lymphocytes is a
hallmark of modulation of the S1P-S1P1 receptor axis and can be
explained by accumulation of S1P in tissues of our S1PL-deficient
genetic models. Our results are consistent with published data
showing that RNA interference–mediated knockdown of S1PL in
hematopoietic cells leads to increased S1P levels and a block in T-
cell egress [28]. In the same study, inhibition of S1PL by the food
colorant THI produced similar results [28]. Our analysis of genetic
models with a wide range of systemic S1PL deficiency extend on
these studies and clearly demonstrate that T-cell trafficking is
particularly tightly controlled by S1PL activity compared to other
physiological processes.
It appears that several mechanisms may be involved in S1PL-
induced inhibition of thymocyte egress and development. It is a
novel finding in our genetic models that excessive S1P levels can
also disturb thymocyte development in addition to T-cell egress,
leading to decreased thymic cellularity and T-cell output. This is
most clearly evidenced in S1PL
2/2 mice by the severe
hypocellularity and increased apoptosis of lymphocytes within
the thymic cortex, and by the paucity of T-cells in the splenic
PALS and paracortical areas of lymph nodes. It is possible that
stress-related elevations in glucocorticoid levels could have
contributed to lymphocyte apoptosis and hypocellularity in the
thymic cortex of S1PL
2/2 mice; however, the lymphoid
hypercellularity in the thymic medulla of these mice is not
generally a feature of stress-induced thymic atrophy, suggesting
that direct S1PL effects are involved. Direct S1PL effects on
lymphocyte development in the thymus are also suggested by the
lymphoid hypocellularity and increased apoptosis of lymphocytes
we observed in the thymic cortex of clinically normal S1P
H/2
mice; these mice retained low level S1PL activity and the cortical
lymphoid depletion was unlikely to be stress related. S1P has been
Figure 12. Human S1PL knock-in results in partial rescue of KO hematopoietic cell profile. (A) Blood cell counts were obtained from 62–
75 mice of each genotype pooled from seven independent experiments giving similar results. Total thymocyte counts and fractions of SP and DN
cells were determined from 3 and 15 mice of each genotype, respectively. Data are presented as described in Fig. 2A and B; *P,0.02, S1PL
H/H vs.
S1PL
+/+.( B) Representative FACS plots show the CD69/CD62L Ab staining patterns of SP thymocytes from the indicated mice, identified by single
expression of either the CD4 or CD8 markers. Data are presented as described in Fig. 7. Samples from 11 additional mice of each treatment group
gave similar results.
doi:10.1371/journal.pone.0004112.g012
Figure 13. Lymphopenia correlates proportionally with the
extent of S1PL deficiency. Blood cell counts were obtained from 75
and 30 mice carrying 2 copies or a single copy of the human knockin
allele, respectively. Data are presented as described in Fig. 12A.
doi:10.1371/journal.pone.0004112.g013
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mammalian cells [2,6–8,10–13], and the S1P1 receptor-agonist
FTY720 affects thymocyte apoptosis in mice and rats [44,45]. In
addition to its direct effect on apoptosis, excess tissue concentra-
tions of S1P may also interfere with lympho-stromal interactions.
In S1PL
2/2 mice, thymic epithelial cells and stromal cells that are
required for T-cell selection and maturation, were highly
vacuolated, which might compromise their function. The severe
vacuolization of epithelial cells in the thymic cortex was largely
reversed by low-level expression of S1PL in the humanized mice,
but the thymus of these mice still registered a 60% reduction in
thymic cellularity. Despite this apparent thymic hypocellularity, no
loss of either the progenitor DN T-cell population or the mature
T-cell population in the thymus was observed in the humanized
mice. This suggests that loss of S1PL activity impedes the
intermediary steps of T-cell maturation, which are dependent
upon a complex set of lympho-stromal interactions [46].
Furthermore, we observed sequestration of lymphocytes in the
thymic medulla and lymph nodes of the humanized mice but not
in the spleen. These findings are consistent with some published
reports that S1P-mediated retention of lymphocytes is prevalent in
the thymus and lymph nodes but not in spleen, which further
suggests that a tissue-specific stromal component may be involved
in the S1P1 receptor-mediated control of lymphocyte trafficking
[25,38,46]. It must be noted however that the absence of
significant sequestration of lymphocytes in the spleen in our
studies is in apparent conflict with other recent reports that
provided evidence supporting a role for S1P in egress of both B-
cells [32] and T-cells [47] from the spleen.
Our finding that S1PL inhibition had a much lesser impact on
B-cell homeostasis than its effects on T lymphocytes is consistent
with reported differences in the ability of FTY720 or the S1PL
inhibitor THI to retain T- versus B-lymphocytes [28,30,32]. We
detected B-cell development abnormalities only in the S1PL
2/2
bone marrow. Similarly, increased myeloid cell numbers in the
peripheral blood and infiltration of the peripheral organs was
evident only in S1PL
2/2 mice. One explanation for the increased
myeloid cell activity may be that the mobilized neutrophils and
phagocytes are involved in eliminating apoptotic cells that
accumulate in the infiltrated organs. Similar myeloid cell
infiltration was observed in the thymus, spleen and LN of lpr
mice after treatment with FTY720 which induced apoptosis in
these organs [48]. Consistent with this explanation is our finding
that neutrophil granulocytes of S1PL
2/2 mice show a significantly
decreased expression of CD62L (our unpublished data), an
adhesion molecule which is shed from the cell surface after cell
activation, implying that granulocytes are in an activated state in
these animals.
In contrast to the failed rescue of immune system phenotypes in
our humanized mice, we found that even minimal S1PL activity
was sufficient to prevent the development of significant lesions in
non-lymphoid tissues. Among the non-lymphoid tissues, the
urothelium appeared to be the most sensitive to reduced S1PL
activity. Urothelial lesions could be caused by a direct effect of
S1PL deficiency in urothelial cells or by excreted sphingolipid
metabolites present in the urine. However, urothelial lesions were
entirely absent in young adult humanized mice and were minimal
in aged S1PL
H/2 and S1PL
H/H mice. Similarly, lung pathology
was not present in either of the genetic models expressing partial
S1PL activity. Respiratory distress caused by pulmonary lesions
was the most likely cause of reduced viability of S1PL
2/2 mice, as
accumulations of proteinaceous exudates lining and partially filling
alveoli would impair alveolar gas exchange. It is likely that the
extremely elevated levels of extracellular S1P played a direct role
in the development of the pulmonary lesions in the complete S1PL
knockouts. One of the S1P receptors, S1P3, is expressed on
alveolar epithelial cells, and airway administration of S1P has been
shown to disrupt epithelial cell tight junctions and induce
pulmonary edema [49]. It is likely that S1P levels are elevated in
the alveoli of S1PL
2/2 mice and that activation of alveolar
epithelial S1P3 might compromise the integrity of the pulmonary
epithelial barrier. In addition, impaired function of the distended
alveolar macrophages in lungs of S1PL2/2 mice may also have
contributed to the accumulation of proteinaceous alveolar
exudates. Mutations that directly impair the development and/
or function of alveolar macrophages [50], as well as mutations that
inhibit degradation of surfactant within these cells, have been
shown to result in alveolar proteinosis and pulmonary dysfunction
in both mouse and human [51]. Surfactant dysregulation has also
been proposed as a common pathogenic mechanism of several
sphingolipid storage disorders [52].
The increased interstitial cellularity and vacuolation in the
myocardium and osteopetrosis seen with the S1PL
2/2 mice also
resolved with the minimal enzyme reconstitution in the humanized
mouse lines. The myocardial lesions, while not clearly degener-
ative, suggest that myocardial homeostasis was altered. The
molecular mechanisms responsible for the bone phenotype in the
S1PL
2/2 mice are unclear at this point since studies have
implicated S1P signaling in both osteoclast and osteoblast function
[53]. However, S1PL
2/2 mice had an increased volume of
trabecular bone in both sternebra and long bones (osteopetrosis).
Bone normally undergoes a constant process of remodeling carried
out by osteoclasts which resorb old bone and osteoblasts,
generating new bone. The osteopetrosis seen in S1PL
2/2 mice
appears to be the result of dysfunctional osteoclasts. The enlarged
osteoclasts in S1PL
2/2 mice were distended by intracellular
accumulations of granular eosinophilic material and were
generally detached from the bone surfaces, and would therefore
be physically unable to form the tight junctions and ruffled borders
required for effective bone resorption.
In summary, we found that loss of S1PL activity in S1PL
2/2
mice results in severe T-cell depletion in the blood, thymus, spleen,
and lymph nodes, as well as lesions in the lung, heart, urinary
system, and bone, and that the observed reduced viability of
S1PL
2/2 mice is most likely due to respiratory failure. Partial
restoration of S1PL activity in humanized mice rescued lesions in
lung, bone, and urothelium, but failed to restore normal T-cell
development and trafficking. Thus, comparative analysis of genetic
mouse models having differing levels of S1PL activity suggests that
the S1P pathway is more stringently controlled in the immune
system than in the non-lymphoid environment. The relatively
specific physiological response to partial inhibition of S1PL activity
suggests that there is a window within which reduced S1PL activity
could produce potentially therapeutic immunosuppression without
causing clinically significant S1P-related lesions in non-lymphoid
target organs. Immunosuppression induced by inhibiting S1PL
activity has potential application in the treatment of a variety of
autoimmune and inflammatory diseases, and the humanized S1PL
mouse line provides an attractive model for studying small
molecule inhibitors of the human enzyme.
Materials and Methods
Experimental Animals
All mice analyzed were maintained on a mixed genetic
background (129S5/SvEvBrd and C57BL/6J) at the ALAAC-
accredited animal facility at Lexicon Pharmaceuticals Inc. Studies
of gene-disrupted or humanized animals were performed using Wt
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22uC on a fixed 12-hour light and 12-hour dark cycle and were fed
rodent chow # 5001 (Purina, St. Louis, MO) ad libitum. Procedures
involving animals were conducted in conformity with the
Institutional Animal Care and Use Committee guidelines that
are in compliance with the state and federal laws and the standards
outlined in the Guide for the Care and Use of Laboratory
Animals.
Generation of S1PL KO mice
Homozygous S1PL-null mice were generated by gene trapping
as previously described [41,54]. OmniBank embryonic stem cell
clone OST58278 was selected for microinjection based on
sequence similarity to the mouse S1PL gene (accession number
NM_009163). The genomic insertion site of the gene trap vector
in OST58278 was determined by inverse PCR [54] (Fig. 1A).
Mice carrying this mutation were generated by using standard
methods of host embryo microinjection of embryonic stem cells,
chimera production, and germ-line transmission [54]. Animal
genotypes were determined by quantitative PCR [54] (Fig. 1B).
Generation of human S1PL knockin allele
The first coding exon of the mouse S1PL gene was replaced
with the human S1PL cDNA using the Lambda KOS system [55].
The Lambda KOS library was screened by PCR using the
following primers: 59-GCTTTTGCTCAAAGCTCAGC-39 and
59-TGTACCTGCTAAGTTCCAGG-39. A single genomic clone
(pKOS-15) was isolated and confirmed by sequence analysis.
Gene-specific arms 59-AGCCCCGGGGAGGGAGCCGGCTG-
CAGAGGAAG-39 and 59-CTCAGAGCCTTCTGAGCGAGA-
GAGAAAGGA-39 were appended by PCR to a yeast selection
cassette containing the URA3 marker. The yeast selection cassette
and pKOS-15 were co-transformed into yeast, and clones that had
undergone homologous recombination to replace a 37 bp region
containing the first coding exon of S1PL with the yeast selection
cassette were isolated. The yeast cassette was subsequently
replaced with a cassette containing a spliceable mini-gene, the
human S1PL cDNA and the Neo selectable marker flanked by
LoxP sites (Fig. 11A). The linearized targeting vector was
electroporated into 129S5/SvEvBrd embryonic stem cells that
contain a Protamine-driven Cre recombinase transgene to allow
excision of Neo in the germline of transgenic animals [56]. RT-
PCR analysis was used to demonstrate expression of the human
cDNA (Fig. 8B).
Measurement of S1PL activity
Spleens of mice were homogenized in ice-cold buffer containing
50 mM KPO4, pH 7.5, 1 mM EGTA, 1 mM DTT, and complete
protease inhibitor cocktail (Roche Applied Science, Indianapolis,
IN). The homogenate was centrifuged at 2,5006g for 10 minutes,
and the supernatant was used for enzyme activity measurements.
Protein concentration was determined using the Bradford method.
S1PL activity was determined using
33P-labeled S1P as substrate.
The reactions were carried out in a 50 ml volume containing
100 mM KPO4, pH 7.4, 1 mM EDTA, 25 mM NaF, 5 mM
DTT, phosphatase inhibitors I & II (Sigma-Aldrich), 0.1% Triton
X-100 and various amounts of tissue lysate. The reactions were
initiated by addition of pyridoxal phosphate (final concentration
50 mM) and 15 nCi of [
33P]-S1P (specific activity 0.6 Ci/mmol,
total S1P concentration 0.5 mM). The reaction mixtures were
incubated at 37uC for 1 hour and terminated with the addition of
90 ml of 35% acetonitrile containing 0.1% TFA. A total of 120 ml
of the mixtures were then transferred to a 96-well C18 multi-SPE
plate (Millipore Corporation, Bedford, MA) pre-equilibrated first
with 100 ml MeOH and then with 200 ml 20% acetonitrile
containing 0.1% TFA. The plate was briefly centrifuged at
3,000 rpm for 1 minute and the filtrate was collected and assayed
for
33P activity by scintillation counting. These reactions were
performed in the presence and absence of 2.5 or 5 mM
semicarbazide, a reactive compound that inhibits S1PL activity
[57]. Activities reported represent the semicarbazide-sensitive
portion of the total activity.
Measurement of S1P concentration
Extraction of S1P from mouse tissues was performed essentially
as described [58] and dried under N2. S1P levels in dried extracts
were quantitated using a whole cell receptor binding assay [59].
Briefly, S1P extracts or standards were resuspended in 50 ml
binding buffer containing 25,000 cpm [
33P]-S1P (specific activity
0.6 Ci/mmol) and added to 5610
4 HEK293 cells expressing S1P1
receptor. Cells were incubated on ice for one hour then washed
twice with binding buffer. Cells were lysed by addition of 100 ml
lysis buffer and 40 ml of the resulting extract was added to 120 ml
MS40 microscint. S1P content of extracts was estimated from
standard curves (between 42 pM and 2.5 mM) generated with cold
S1P standards.
CBC and flow cytometry
CBC analysis was performed on blood isolated from the
retroorbital sinus of mice anesthetized with isofluorane using either
Cell-Dyn 3500 (Abbott Diagnostics, Abbott Park, IL) or HemaVet
850 FS (Drew Scientific, Inc., Oxford, CT) instruments. For flow
cytometry analysis of whole blood, erythrocytes were lysed by
hypotonic shock, washed once in FACS wash buffer (FWB: PBS/
0.1% BSA/0.1% NaN3/2 mM EDTA) and stained for 30 minutes
at 4uC in the dark with the indicated combination of fluoro-
chrome-conjugated mAbs. After staining, the cells were washed
once with FWB and resuspended in 300 ml FWB for analysis.
Samples were analyzed using a FACSCalibur flow cytometer and
CellQuest Pro software (Becton Dickinson Immunocytometry
Systems, San Jose, CA). Thymus, bone marrow (from two femurs
per mouse), spleen, and lymph nodes (LN) (two inguinal, axillary,
lateral axillary, and mesenteric per mouse) were harvested and
dispersed into single-cell suspensions by forcing the tissue through
a7 0 mm cell strainer (Falcon, Becton Dickinson Labware,
Bedford, MA). Single cell suspensions were analyzed by CBC
and FACS as above except that prior to staining, cells were
incubated with 10 ml antibody (1/10 dilution in FWB, Fc BlockH,
BD BioSciences, San Jose, CA) for 15 min. at 4uC. The following
antibodies (all from BD BioSciences, San Jose, CA) were used in
this study: anti-B220-FITC, -PE, -APC and -PERCP, anti-b7
integrin-FITC and -PE, CD4-FITC, -PE, -APC and -PERCP,
CD8a- FITC, -PE, -APC and -PERCP, CD69-FITC, CD44-APC,
CD24-FITC, -PE and -APC, CD62L-FITC, -PE and –APC,
CD43-PE, CD45- FITC, -PE, -APC and –PERCP. The absolute
number of each indicated cell subset was calculated by multiplying
its fractional representation determined by FACS by the absolute
number of cells identified by CBC. B cells were identified as
CD19
+/CD45
+/TcRb
2 mononuclear cells, T cells as CD4
+ or
CD8
+ and TcRb
+/CD45
+/CD19
2 mononuclear cells.
Histopathology
Tissues collected from genetically modified mice and age-
matched Wt control mice were immersion fixed in 10% neutral
buffered formalin, except eyes, which were fixed for 24 h in
Davidson’s fixative. All tissues were embedded in paraffin,
sectioned at 4 mm, and mounted on positively charged glass slides
S1P Lyase Deficiency in Mice
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hematoxylin and eosin for histopathologic examination.
Statistics
Analysis of statistical significance of group differences was
performed using the two-sample t-test. In all tests, a P value of
,0.05 was considered significant.
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